Clinical Trial

Durvalumab and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a phase II trial of durvalumab and tremelimumab in combination of platinum-based chemotherapy. Patients with stage IV Non-Small-Cell-Lung Cancer (NSCLC) with human immunodeficiency virus (HIV) infection will be eligible. Patients will receive standard platinum-based chemotherapy plus durvalumab for 4 cycles (every 3 weeks), followed by durvalumab (with or without pemetrexed for non-squamous NSCLC) maintenance therapy. It is hypothesized that Durvalumab and tremelimumab in combination with standard chemotherapy is safe and effective for the treatment of stage IV NSCLC in patients with HIV infection.
Protocol Amendment History 13 amendments
This ClinicalTrials.gov record has been amended 13 times since 2020-07-30; most recent amendment 2026-03-12.
Status change: Not Yet Recruiting → Recruiting 2020-12-09
Trial Details
NCT Number NCT04499053
Lead Sponsor Georgetown University
Collaborators: AstraZeneca
Conditions Carcinoma, Non-Small Cell Lung
Enrollment 18 participants
Start Date 2020-12-09
Primary Completion 2027-02 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2026-03-16